Clinical Trials · NCT04039503
A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 475
- Start date
- Aug 2019
- Locations
- 48 sites, 8 countries
- Primary endpoint
- Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)